Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05606159

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

Clostridium Difficile Infection Recurrence Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Tolerability and Effect of Bacillus Velezensis DSM 33864 on the Reduction of Risk of Recurrent Clostridioides Difficile Infection (rCDI) in Adults With a History of rCDI

Clinical Trial Summary

The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in colonization by toxigenic C. difficile. This study will include adults with a history of two episodes of C. difficile infection (CDI).

Clinical Trial Description

The goal of this multi-center randomized double-blinded placebo-controlled trial is to evaluate the tolerability and effect of a probiotic dietary supplement on the reduction of the risk of recurrent C. difficile infection in adults who have experienced two previous C. difficile infection episodes. The main aim of this study is to assess the effect of a probiotic dietary supplement on the colonization (cell counts) of C. difficile over time and also to assess the correlation between level of C. difficile colonization and recurrence of CDI. Approximately, 104 research subjects will be randomized into two arms and will use either one capsule daily of the probiotic supplement or placebo once daily with breakfast, for 8 weeks. All outcomes will be compared across the supplementation and placebo arm. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05606159
Study type Interventional
Source Novozymes A/S
Contact Victoria Oyedokun, PhD
Phone +491723244702
Email vtoy@novozymes.com
Status Not yet recruiting
Phase N/A
Start date November 2023
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04000555 - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Phase 4
Terminated NCT03065374 - Treatment for Clostridium-difficile Infection With IMM529 Phase 1/Phase 2
Completed NCT03110133 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03880539 - Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection Phase 4
Not yet recruiting NCT04415918 - Bezlotoxumab Efficacy and Tolerability in Cancer Patient Phase 4
Recruiting NCT03562741 - Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile N/A
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Completed NCT04891965 - A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) Phase 1
Completed NCT04317963 - Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
Completed NCT03617445 - Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients Phase 2
Recruiting NCT05831189 - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection Phase 3